ARCHIVES

MOPP Consequences, Including Increase In cure Rate, Describe By DeVita

This article is from The Cancer Letter archive.

Vol. 05 No. 21 | May 25, 1979

Download PDF Visit The Full Archive

Related Articles

Virus Studies Approved By DCE Board for $2.5 Mil. In First Year

November 3, 1989

NIH Funding Strategies, UICC Fellowships

December 4, 1992

Cancer Groups Endorse Pazdur For FDA Commissioner.

January 19, 2001

AACI Committee Makes Case For Clinical Research In Centers; Cancer Control, Group Funds Eyed

December 8, 1978

Ibrutinib Increases OS, PFS Versus Ofatumumab in Phase III

June 27, 2014

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

March 29, 2013